These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 38173201

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N, Wang LJ, Jiang B, Li XQ, Guo CL, Guo SJ, Shi DY.
    Eur J Med Chem; 2018 May 10; 151():145-157. PubMed ID: 29609120
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
    Singh AK, Jatwa R, Purohit A, Ram H.
    J Asian Nat Prod Res; 2017 Oct 10; 19(10):1036-1045. PubMed ID: 28351157
    [Abstract] [Full Text] [Related]

  • 7. Drug discovery approaches targeting the incretin pathway.
    Deng X, Tavallaie MS, Sun R, Wang J, Cai Q, Shen J, Lei S, Fu L, Jiang F.
    Bioorg Chem; 2020 Jun 10; 99():103810. PubMed ID: 32325333
    [Abstract] [Full Text] [Related]

  • 8. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.
    Diabetes Metab Res Rev; 2014 Jul 10; 30(5):354-71. PubMed ID: 24989141
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM).
    Shao DW, Zhao LJ, Sun JF.
    Eur J Med Chem; 2024 Jun 05; 272():116464. PubMed ID: 38704940
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies.
    Chen Z, Su X, Cao W, Tan M, Zhu G, Gao J, Zhou L.
    Mar Drugs; 2024 Aug 09; 22(8):. PubMed ID: 39195477
    [Abstract] [Full Text] [Related]

  • 12. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
    Power O, Nongonierma AB, Jakeman P, FitzGerald RJ.
    Proc Nutr Soc; 2014 Feb 09; 73(1):34-46. PubMed ID: 24131508
    [Abstract] [Full Text] [Related]

  • 13. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and de novo Evolution.
    Musoev A, Numonov S, You Z, Gao H.
    Molecules; 2019 Aug 07; 24(16):. PubMed ID: 31394858
    [Abstract] [Full Text] [Related]

  • 14. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
    De S, Banerjee S, Kumar SKA, Paira P.
    Mini Rev Med Chem; 2019 Aug 07; 19(2):88-97. PubMed ID: 29692250
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA, Gallwitz B.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug 07; 23(4):479-86. PubMed ID: 19748065
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD, Flatt PR, Bailey CJ.
    Diab Vasc Dis Res; 2006 Dec 07; 3(3):159-65. PubMed ID: 17160910
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory evaluation of Curculigo latifolia on α-glucosidase, DPP (IV) and in vitro studies in antidiabetic with molecular docking relevance to type 2 diabetes mellitus.
    Zabidi NA, Ishak NA, Hamid M, Ashari SE, Mohammad Latif MA.
    J Enzyme Inhib Med Chem; 2021 Dec 07; 36(1):109-121. PubMed ID: 33249946
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
    Moore KB, Saudek CD.
    Am J Ther; 2008 Dec 07; 15(5):484-91. PubMed ID: 18806525
    [Abstract] [Full Text] [Related]

  • 19. Identification and molecular docking study of sugarcane leaf-derived compounds as potent dipeptidyl peptidase IV, α-glucosidase, and α-amylase inhibitors.
    Kan R, Ren P, Wu A, Tang Q, Kong B, Xue C.
    J Sci Food Agric; 2023 Aug 30; 103(11):5388-5400. PubMed ID: 37038045
    [Abstract] [Full Text] [Related]

  • 20. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
    Avogaro A, Fadini GP.
    Br J Clin Pharmacol; 2018 Aug 30; 84(8):1686-1695. PubMed ID: 29667232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.